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ABSTRAK
Tujuan: untuk menilai keamanan dan efektifitas terapi telbivudine pada pasien dewasa dengan CHB di 
Indonesia. Metode: desain penelitian adalah kohort prospektif. Penelitian multisenter pada pasien CHB dewasa 
yang memerlukan terapi antiviral oral dalam praktik klinis sehari-hari. Seluruh pasien menerima 600 mg 
telbivudine setiap hari selama satu tahun. Rekrutmen dan keputusan untuk memulai terapi telbivudine didasarkan 
pada indikasi klinis yang dinilai oleh dokter yang berpartisipasi. Diutamakan adalah keselamatan pasien (adverse 
event atau efek samping yang serius), sedangkan titik akhir sekunder adalah serokonversi HBeAg, perubahan 
serum tingkat DNA HBV dan serum ALT normalisasi. Pasien dinilai pada minggu ke-24 dan ke-52 setelah terapi. 
Hasil: sebanyak 176 kasus yang memenuhi kriteria untuk dianalisis, 104 (59,8%) HBeAg-positif dan 70 (40,2%) 
pasien HBeAg-negatif. Efek samping yang dilaporkan pada 7 (4,0%) pasien, kebanyakan dari mereka adalah 
ringan. Hilangnya HBeAg dan tingkat serokonversi sebesar 28,8% dan 14,14%, masing-masing pada minggu 
ke-52. Tidak terdeteksi HBV DNA (PCR negatif) 51,8% pada minggu ke-24 dan 62,7% pada minggu ke-52. 
Median tingkat HBV DNA secara signifikan berkurang dari awal sampai minggu ke-24 dan minggu ke-52 
setelah terapi (p<0,001, uji Wilcoxon signed-rank). Normalisasi aktivitas ALT serum terjadi pada 85 (73,28%) 
pasien pada minggu ke-52. Kesimpulan: terapi Telbivudine umumnya aman dan dapat ditoleransi dengan baik 
pada pasien Indonesia dewasa dengan hepatitis B kronis. Pada pengobatan hilangnya HBeAg serokonversi, 
perubahan tingkat HBV DNA, dan normalisasi ALT serum ditemukan hasil yang sama dengan studi sebelumnya.
Kata kunci: Alanine aminotransferase, hepatitis B kronis, HBV DNA, pengobatan antivirus oral, terapi 
telbivudine.
ABSTRACT 
Aim: to assess the safety and efficacy of telbivudine therapy in adult patients with CHB in Indonesia. Methods: 
the study design was prospective cohort study. Multicenter study of adult CHB patients requiring oral antiviral 
therapy in daily practice setting. All patients received 600 mg of telbivudine daily for one year. Recruitment and 
decision to start telbivudine therapy was based on clinical indication as assessed by the participating physicians. 
The primary end-point was patient safety (adverse event or serious adverse events); while the secondary end-
points were HBeAg seroconversion, changes of serum HBV DNA levels and serum ALT normalization. Patients 
were assessed at week-24 and week-52 of treatment. Results: a total of 176 cases were eligible for analysis, 
comprising 104 (59.8%) HBeAg-positive and 70 (40.2%) HBeAg-negative patients. Adverse events were reported 
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in 7 (4.0%) patients, most of them were mild. HBeAg loss and seroconversion rate was 28.8% and 14.14% at 
week-52 respectively. Undetectable HBV DNA (PCR negativity) was 51.8% at week-24 and 62.7% at week-52. 
Median HBV DNA levels were significantly reduced from baseline to week-24 and week-52 treatment (both 
p<0.001; Wilcoxon’s signed-rank test). Normalization of serum ALT activity occurred in 85 (73.28%) patients at 
week-52. Conclusion: Telbivudine therapy is generally safe and well tolerated among adult Indonesian patients 
with chronic hepatitis B. Treatment efficacy in terms of HBeAg loss and seroconversion, changes of HBV DNA 
levels and serum ALT normalization were similar to previous reported studies.
Key words: Alanine aminotransferase, chronic hepatitis B, HBV DNA, oral antiviral treatment, telbivudine 
therapy.
INTRODUCTION
Chronic hepatitis B (CHB) is still a major 
public health problem in Indonesia. Persistence 
of active hepatitis B virus (HBV) infection 
is associated with morbidity and mortality in 
CHB due to the progression to cirrhosis or 
hepatocellular carcinoma.1,2 Based on the Asia 
Pacific Association for the Study of the Liver 
(APASL) guidelines,antiviral treatment is 
indicated for CHB patients with serum alanine 
aminotransferase (ALT) activity more than twice 
the upper limit of normal (>2x ULN) and HBV 
DNA levels ≥105in HBeAg-positive or ≥104 
copies/mL in HBeAg-negative patients.3
The long-term goal of CHB treatment is 
to prevent disease progression to cirrhosis, 
HCC and death caused by HBV replication and 
liver inflammation.4 Unfortunately, complete 
eradication of HBV infection is impossible due 
to the persistence of covalently closed circular 
DNA (cccDNA) in the hepatocytes nuclei.5,6 
Therefore, the main aims of treatment are to 
achieve HBeAg seroconversion or undetectable 
HBV DNA levels or both; stop or reduce 
hepatic necroinflammation; and prevent hepatic 
decompensation.
Telbivudine demonstrated potent activity 
against hepatitis B with a significantly higher 
rate of response and superior viral suppression 
compared with lamivudine, the standard 
treatment.7,8 Telbivudine has been introduced in 
Indonesia since 2006 but has not been studied 
in Indonesian population. This study design is 
aligned with the roadmap concept to optimize 
therapy in CHB patients.9 Central to this concept 
is the use of on-treatment monitoring strategies 
of early virologic responses which may be 
predictive of improved outcomes, including 
reduced risk of anti-viral resistance. This study 
is primarily designed to assess the safety and 
efficacy of telbivudine therapy in adult patients 
with compensated CHB in Indonesia.
METHODS
This was an observational, prospective 
cohort, multicenter study of CHB patients treated 
with telbivudine.and was funded by Novartis 
pharma. Study was conducted on 184 patients 
from 191 physicians in 7 cities in Indonesia from 
April 2009 to November 2011.
Inclusion criteria were male or female adult 
patients, aged more than 18 years, diagnosed 
with CHB by positive HBsAg for at least 6 
months, had HBeAg-positive or -negative, had 
a clinical history compatible with CHB, and no 
prior history of CHB treatment. Patients were 
excluded if there was a known hypersensitivity 
to telbivudine or any of its ingredients, was 
pregnant or intended to become pregnant or 
planned to breastfeed during the study period, or 
had any clinically significant concurrent severe 
or unstable medical conditions. Ethical approval 
was obtained from the Ethical Committee 
of Medical Research, Faculty of Medicine, 
University of Indonesia.
Data Collection
Data were collected and recorded in a written 
case report form (CRF) specifically designed for 
this study. Assessments and evaluations were 
performed according to the physician’s routine 
practice and standard care. Data included patient 
demographics, background characteristics, 
details of the hepatitis B related medical history, 
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concomitant diseases, vital signs, laboratory 
values, adverse events, compliance, and a final 
physicians assessment of the therapy with regard 
to effectiveness, safety, and tolerability.
Clinical and Laboratory Assessment
Patients were expected to complete a follow-
up period of 52 weeks, including treatment 
response evaluation at week-24 and week-52. 
Assessment included safety profile, including 
the number and type of adverse events (AEs) or 
serious AEs; virological response (HBeAg loss 
and seroconversion; serum HBV DNA level 
changes; PCR negativity (<300 copies/ mL or 
60 IU/mL); and normalization of serum ALT 
enzyme activity (<1x ULN).
Statistical Analysis
Data from the CRF were entered into an 
electronic database in the Clinical Study Unit, 
Faculty of Medicine, University of Indonesia. 
Patients’ demographic and baseline data were 
presented descriptively as percentage for 
categorical data or mean and standard deviation 
(SD) for numerical data. Due to well-recognized 
clinical differences of HBeAg-positive and 
HBeAg-negative CHB patients,10,11 analyses 
were done separately for both groups. Adverse 
and serious adverse event data were presented 
and analyzed descriptively. HBeAg loss, HBeAg 
seroconversion, PCR negativity, and serum ALT 
normalization were also presented and analyzed 
descriptively. Median serum HBV DNA changes 
were analyzed using the Wilcoxon’s signed-rank 
test for skewed data. A p value less than 0.05 was 
considered significant. Statistical analysis was 
done using SPSS version 17.0 for Windows PC 
(SPSS Inc., Chicago, Illinois).
RESULTS
Characteristics of the Study Subjects
Two hundred and twenty three patients were 
recruited for this study; 39 patients did not return 
after baseline visit, resulting with 184 patients to 
be evaluated for safety analyses. Eight patients 
had undetected HBV-DNA levels at baseline and 
were excluded (Figure 1). The final number of 
patients available for efficacy analyses was 176 
patients, comprising 106 (60.2%) men and 70 
(39.8%) women. Patients mean age was 41.5 
years, ranging from 18-70 years old; the basic 
characteristic of the 176 patients are shown in 
Table 1.
Safety Analysis
The adverse events were reported in 7 (3.8%) 
patients, most of them were mild. Adverse events 
were abdominal discomfort (2), neuropathy (1), 
common cold (1), nausea (1), myotoxicity (1), 
death (1), and pregnancy (1). The latter was 
reported by a patient who had a musculoskeletal 
problem, i.e. spondyloarthritis, and was not 
related to telbivudine therapy.
Telbivudine treatment was discontinued in 
one patient because of unexpected pregnancy. 
Later she gave birth to a healthy baby boy. 
Efficacy Analysis
Evaluation of treatment response was done at 
week-24 and week-52 for all patients receiving 
treatment. Among HBeAg-positive patients, 
9.18% patients achieved HBeAg loss at week 24 
and 23.23% at week 52; while seroconversion 
was detected in 5.10% at week-24 and 14.14% 
at week-52 (Figure 2).
Seventy-two out of 139 patients (51.8%) 
had undetectable HBV DNA levels (PCR 
223 subjects enrolled:
Jakarta: 120 subjects
Surabaya: 28 subjects
Bandung: 22 subjects
Medan: 21 subjects
Banjarmasin: 18 subjects
Makassar: 10 subjects
Surakarta: 4 subjects
39 subjects did not return
after baseline visit
184 subjects included in the
safety analysis
8 subjects had undetected
HBV-DNA levels at baseline
176 subjects included in the
efficacy analysis
Figure 1. Flow of subjects throughout the study
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negativity) after 24 weeks of treatment and 
increased to 62.5% after 52 weeks of treatment. 
PCR negativity was more profound in HBeAg 
negative-patients (Table 2). In both HBeAg 
positive and negative patients, there was a 
significant reduction of median HBV DNA 
level from baseline at week-24 and week-52 of 
treatment (Table 2). There were 170 patients 
provided with serum ALT level at week-52. 
Normalization of serum ALT activity occurred 
in 73.28% patients (Table 2).
DISCUSSION
Our study is the largest prospective, 
observational study of CHB patients receiving 
telbivudine done in Indonesia. More male 
patients participated in this study, which was 
also reported in many clinical trials,12-14 including 
GLOBE trial.15 For the global prevalence of 
HBV infection between male and female is 
almost similar, 3.9% in men and 3.5% in women. 
However, the prevalence is higher in Southeast 
Asia (5% to over 6%).16 HBeAg-negative 
patients were older than HBeAg-positive patients 
which was consistent with the natural history 
ofchronic HBV infection.17
From our study, telbivudine therapy was 
generally safe and well tolerated, which was 
similar to GLOBE Studies. Adverse events 
were reported in 7/184 (3.8%) patients, most 
of them were mild. Types of adverse events 
were abdominal discomfort (2), neuropathy (1), 
common cold (1), nausea (1), myotoxicity (1), 
death (1), and pregnancy (1). Since the AEs 
were reported by patients during each visit, 
and occurred shortly before visit, they were 
estimated unlikely to be related to telbivudine. 
Table 1. Baseline characteristics of the study subjects (n=176)
Characteristic
All patients* 
(n=176)
HBeAg (+) 
(n=104)
HBeAg (-) 
(n=70)
Gender, n (%)
 - Male 106 (60.2) 61 (58.7) 43 (61.4)
 - Female 70 (39.8) 43 (41.3) 27 (38.6)
Age, mean (SD) 41.5 (12.37) 37.9 (12.11) 46.8 (11.01)
 - <40 years, n (%) 79 (44.9) 61 (58.7) 17 (24.3)
 - >40 years, n (%) 93 (52.8) 41 (39.4) 51 (72.9)
AST level (U/L), mean (SD) 99.8 (159.06) 90.0 (126.68) 115.6 (197.97)
ALT level (U/L), mean (SD)** 114.9 (169.58) 119.1 (192.71) 110.4 (133.66)
 - <2x ULN, n (%) 108 (61.4) 61 (58.7) 45 (64.3) 
 - 2-5x ULN, n (%) 41 (23.3) 28 (26.9) 13 (18.6)
 - >5x ULN, n (%) 23 (13.1) 11 (10.6) 12 (7.1)
Albumin (g/dL), mean (SD) 4.2 (0.61) 4.2 (0.58) 4.1 (0.64)
Bilirubin (mg/dL), mean (SD) 1.4 (1.77) 1.2 (1.68) 1.7 (1.86)
HBV DNA (copies/mL)
 - Median 7.45 x 105 9.5 x 105 8.2 x 104
 - Range 107 - 2.6 x 109 107 x 104-2.6 x109 462 - 6.9 x 108
* 2 patients have missing HBeAg data, thus total patients is 176 while HBeAg(+) plus HBeAg (-) is 174.
** Normal limit was 50 U/L for men and 34 U/L for women
9.18%
5.1%
23.23%
14.14%
HBeAg loss HBeAgseroconversion
Week-24 Week-52
Figure 2. HBeAg loss and seroconversion after treatment
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For myotoxicity, the patient had specific 
musculoskeletal abnormality in the form of 
spondyloarthritis which probably caused this 
AE. This abnormality could lead to instability 
and fall. Thus, the presence of myotoxicity in this 
case as well as its relationship with telbivudine 
is questionable.
Other studies have shown the incidence 
of myopathy, characterized by myalgia and 
increase in creatine kinase levels, was from 1.1 
- 1.7% with telbivudine.18 Creatine kinase levels 
were not part of the routine assessment in CHB 
management in normal daily practice; therefore, 
assessment of this particular side effect was not 
done in our study population.
Regarding its efficacy, our study showed 
similar benefit with previous studies (Globe 
and 2303 study). At week-52, HBeAg loss was 
found in 23.23% of the patient population while 
seroconversion was found in 14.14% of the 
patient population. This result is similar to what 
was shown in the 52 week Globe trial results 
(25.7% HBeAg loss and 22.5% seroconversion), 
respectively.15 From these results, it can be 
concluded that telbivudine therapy is efficacious 
for CHB treatment in the Indonesian population.19
Undetectable serum HBV DNA levels by 
PCR at week-24 were similar with the results 
Table 2. Treatment response at week-24 and week-52 (n=176)
Treatment endpoint
HBeAg-positive (n=102) HBeAg-negative (n=70)
Week 24 Week 52 Week 24 Week 52
HBV DNA levels (copies/mL)
Median 1.23 x 103 150 Undetected Undetected
Range Undetected-1.1x108 Undetected-1.1x108 Undetected-3.8x104 Undetected-1.1x108
p from baseline* <0.001 <0.001 <0.001 <0.001
HBV DNA status by PCR
 - Positive 56 (71.8%) 50 (56.2%) 10 (16.9%) 6 (9.8%)
 - Undetected 22 (28.2%) 39 (43.8%) 49 (83.1%) 55 (90.2%)
Total 78 (100.0%) 89 (100%) 59 (100%) 61 (100%)
p between visit 3 & 4 0.000 0.000
Serum ALT status
 - Above ULN 34 (34.7%) 26 (26.3%) 14 (20.3%) 10 (14.5%)
 - <1x ULN 64 (65.3%) 73 (73.7%) 55 (79.7%) 59 (85.5%)
Total 98 (100%) 99 (100%) 69 (100%) 69 (100%)
p between visit 3 & 4 0.000 0.000
*Wilcoxon’s signed-rank test
from the GLOBE trial, i.e. 45% in HBeAg-
positive and 80% in HBeAg-negative patients. 
However, at week-52, our results were lower than 
the GLOBE trial which had PCR negativity of 
60% in HBeAg-positive and 88.3% in HBeAg-
negative patients.15
Early HBV DNA suppression during CHB 
treatment is important to predict long-term 
outcomes. A recent study of telbivudine in 117 
treatment-naïve CHB patients (61.5% HBeAg-
positive) showed that serum HBV DNA <200 
IU/ mL at week 12 was predictive of favorable 
long-term outcomes, increase cumulative rates 
of HBeAg seroconversion, ALT normalization, 
and HBV DNA undetectability.18
In our study, 73.28% of patients who came 
for the last follow-up visit at week-52 showed 
normalization of serum ALT levels. In GLOBE 
trial, the rates of normalization of serum ALT at 
week-52 were reported more than 70% in patients 
treated with telbivudine.15 After two-years, ALT 
normalization occurred in more than 80% of 
patients.19
Higher serum ALT levels at baseline could 
predict a higher rate of HBeAg seroconversion 
with long-term telbivudine therapy. HBeAg 
seroconversion was reported as high as 17.8% 
in patients with serum ALT <2x ULN, 32.3% in 
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patients with serum ALT 2-5x ULN, and 46.3% 
in patients with serum >5x ULN respectively.20
CONCLUSION
Telbivudine therapy is generally safe and 
well tolerated among adult Indonesian patients 
with chronic hepatitis B. Telbivudine is effective 
to produce HBeAg loss, seroconversion, 
suppress HBV DNA and normalization of serum 
ALT levels. In terms of efficacy measures, results 
from this study are comparable with results from 
the GLOBE trial.
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